The phase II KEYNOTE‐158 trial also showed a similar ORR (14.6%, 95% CI 7.8–24.2) and durable response with pembrolizumab monotherapy in PD‐L1 positive, previously treated advanced cervical cancer, with tolerable side effects.31 The gene discussed is CD274; the disease is cervical carcinoma.